18:10 , Apr 23, 2019 |  BioCentury  |  Finance

Accelerating innovations in Cambridge

As the Cambridge, U.K., life sciences start-up environment continues to flourish, Cambridge Innovation Capital’s Michael Anstey believes the city lacked a crucial element to foster start-ups’ growth: a “true U.S.-style accelerator” to provide capital, mentorship...
22:26 , Apr 1, 2019 |  BioCentury  |  Finance

Backing Cambridge's AI boom

After raising £150 million ($196 million) in its latest fund, Cambridge Innovation Capital will be keeping an eye on how artificial intelligence and machine learning technology can be applied to the life science sector. CIC...
20:44 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

FDA approves Shire's constipation drug

FDA approved Motegrity prucalopride from Shire plc (LSE:SHP; NASDAQ:SHPG) on Dec. 14 to treat chronic idiopathic constipation (CIC) in adults. The approval came a week ahead of the drug's Dec. 21 PDUFA date. Shire markets...
21:36 , Dec 14, 2018 |  BC Extra  |  Company News

FDA approves Shire's constipation drug

FDA approved Motegrity prucalopride from Shire plc (LSE:SHP; NASDAQ:SHPG) to treat chronic idiopathic constipation (CIC) in adults. The approval came a week ahead of the drug's Dec. 21 PDUFA date. Shire markets prucalopride, an agonist...
20:05 , Nov 26, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling A Bayesian network-based method of analyzing non-silent mutations could help identify mutational interactions across different cancer types to predict patient outcomes and identify targets or new indications for drugs. The method involves...
20:01 , Nov 2, 2018 |  BC Week In Review  |  Company News

Synergy evaluating options following slow Trulance uptake

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) said it is evaluating strategic alternatives, including seeking bankruptcy protection, following slower-than-anticipated sales of gastrointestinal drug Trulance plecanatide. The company said it is projecting net sales for Trulance for 2018 of...
19:37 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

FDA panel votes in favor of Shire’s constipation product

FDA’s Gastrointestinal Drugs Advisory committee voted unanimously in favor of approving an NDA from Shire plc (LSE:SHP; NASDAQ:SHPG) for prucalopride to treat chronic idiopathic constipation (CIC). Its PDUFA date is Dec. 21. The panel voted...
18:38 , Oct 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Porphyria In vitro , cell culture and mouse studies suggest ciclopirox could help treat congenital erythropoietic porphyria (CEP), which is caused by destabilizing mutations in UROS. Fragment-based screening, structural comparison of the top screening...
20:38 , Oct 17, 2018 |  BC Innovations  |  Translation in Brief

Ciclopirox the chaperone

Atlas Molecular Pharma S.L. plans to repurpose antifungal drug ciclopirox to treat congenital erythropoietic porphyria after discovering it allosterically stabilizes an enzyme driving the disease. Atlas and colleagues from Center for Cooperative Research in Biosciences...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...